A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Alzheimers Res Ther · 2021 · PMC8157623 · PMID 34044875

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendP =0.068so close (0.05 < p ≤ 0.1)

Furthermore, CSF neurogranin levels showed a trend [−21.0 (−43.6, 1.6) P =0.068] towards improvement with neflamapimod treatment, relative to placebo administration.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.